Lyrica CR 330 mg Extended-Release Tablets, 30 Tablets/Bottle

Lyrica CR — 330MG, Tablet, Film Coated, Extended Release, bottle of 30 tablets

Lyrica CR (PREGABALIN) is a tablet, film coated, extended release for oral use. LYRICA CR is indicated for the management of: • Neuropathic pain associated with diabetic peripheral neuropathy • Postherpetic neuralgia Efficacy of LYRICA CR has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures. LYRICA CR is indicated for the management of: • Neuropathic pain associated with diabetic peripheral neuropathy (DPN) ( 1 ) • Postherpetic neuralgia (PHN) ( 1 ) Efficacy of LYRICA CR has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures.

• Active ingredient or product type: PREGABALIN
• Strength/concentration: 330MG
• Dosage form and route: Tablet, Film Coated, Extended Release, Oral
• Exact package presentation: bottle of 30 tablets
• NDC/item number: 58151-247-93
• Manufacturer: VIATRIS INC
• Storage/handling: Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F) in the original package. (See USP Controlled Room Temperature)
• Status: Rx only

Important safety information: • Angioedema : Angioedema [e.g., swelling of the face, mouth (tongue, lips, and gums) and neck (throat and larynx)] can occur and may be associated with life-threatening respiratory compromise requiring emergency treatment.

Refer to the current product labeling for complete indications, preparation or administration instructions, contraindications, warnings, precautions, and storage requirements.